Guidance for management of cancer surgery during the COVID-19 pandemic.
Journal
Canadian journal of surgery. Journal canadien de chirurgie
ISSN: 1488-2310
Titre abrégé: Can J Surg
Pays: Canada
ID NLM: 0372715
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
entrez:
29
4
2020
pubmed:
29
4
2020
medline:
1
5
2020
Statut:
ppublish
Résumé
During the coronavirus disease 2019 (COVID-19) pandemic, delaying lifesaving cancer surgeries must be done with extreme caution and thoughtfulness. Modelling indicates that delays in high-risk cancer surgeries beyond 6 weeks could affect long-term outcomes for thousands of Canadians. Consequently, it is possible that postponing cancer surgery without consideration of its implications could cost more lives than can be saved by diverting all surgical resources to COVID-19. This article provides general guidance on supporting curative surgical treatment where appropriate and with available resources.
Identifiants
pubmed: 32343118
doi: 10.1503/cjs.005620
pmc: PMC7828991
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S2-S4Informations de copyright
© 2020 Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
J. Bentley is a member of the advisory boards of AstraZeneca and NSV Tech, and his institution receives funding from Merk, AstraZeneca and Clovis for trials he is involved in. T. Zhong is supported by a Canandian Institutes of Health Research (CIHR) New Investigator Award (2015–2020) and she is the inaugural Belinda Stronach Chair in Breast Cancer Reconstruction Surgery at the University Health Network (2017–2022). C. Ball is co-editor in chief of CJS; he was not the accepting editor on this manuscript. No other competing interests were declared.